Clinical Study of ART-123 for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis

NCT02739165 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

74

Enrollment

INDUSTRY

Sponsor class

Conditions

Idiopathic Pulmonary Fibrosis

Interventions

DRUG: ART-123
DRUG: Placebo

Sponsor

Asahi Kasei Therapeutics Corporation